» Articles » PMID: 31239456

The Impact of Levodopa Therapy-induced Complications on Quality of Life in Parkinson's Disease Patients in Singapore

Overview
Journal Sci Rep
Specialty Science
Date 2019 Jun 27
PMID 31239456
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to investigate the impact of levodopa therapy-induced complications on the quality of life (QoL) of Parkinson's disease (PD) patients in Singapore over a 1-year follow-up period. 274 PD patients were prospectively recruited, of which 78 patients completed the follow-up. Patients were evaluated on: (1) motor symptoms, (2) non-motor symptoms, (3) levodopa therapy-induced complications and (4) QoL. Levodopa-induced complications including dyskinesia and OFF symptoms occurred in 13.5% and 55.9% of the study population, respectively. In patients who completed the 1-year follow-up, there was a trend suggestive of increasing dyskinesia duration, more disabling dyskinesia as well as longer, more sudden and unpredictable OFF periods. There was a significant decline in the overall QoL at follow-up, in particular, activities of daily living, emotional well-being, cognition and communication domains were the most affected. The multivariable analysis demonstrated that worsening of UPDRS IV total score over 1-year interval was associated with worsening in PDQ-Summary Index score (d = 0.671, p = 0.014). In conclusion, levodopa-induced complications had significant adverse impacts on QoL. This study substantiates the importance for clinicians to closely monitor and promptly manage levodopa therapy-induced complications that may arise in patients.

Citing Articles

The impact of fatigue severity and depression level on the quality of life in individuals with Parkinson's disease in Taiwan.

Lin H, Lin Y, Chiou C, Pan H Front Psychiatry. 2024; 15:1309989.

PMID: 39100849 PMC: 11294622. DOI: 10.3389/fpsyt.2024.1309989.


Neuroprotective Effect of Phloretin in Rotenone-Induced Mice Model of Parkinson's Disease: Modulating mTOR-NRF2-p62 Mediated Autophagy-Oxidative Stress Crosstalk.

Shirgadwar S, Kumar R, Preeti K, Khatri D, Singh S J Alzheimers Dis. 2022; 94(s1):S109-S124.

PMID: 36463449 PMC: 10473071. DOI: 10.3233/JAD-220793.


Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson's Disease: A Perspective Through Preclinical and Clinical Evidence.

Bandopadhyay R, Mishra N, Rana R, Kaur G, Ghoneim M, Alshehri S Front Pharmacol. 2022; 13:805388.

PMID: 35462934 PMC: 9021725. DOI: 10.3389/fphar.2022.805388.


Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.

Kovacs N, Bergmann L, Anca-Herschkovitsch M, Cubo E, Davis T, Iansek R J Parkinsons Dis. 2022; 12(3):917-926.

PMID: 34974438 PMC: 9108584. DOI: 10.3233/JPD-212979.


Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update.

Prasad E, Hung S Pharmaceuticals (Basel). 2021; 14(8).

PMID: 34451813 PMC: 8398928. DOI: 10.3390/ph14080717.


References
1.
Tomlinson C, Stowe R, Patel S, Rick C, Gray R, Clarke C . Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010; 25(15):2649-53. DOI: 10.1002/mds.23429. View

2.
Soh S, Morris M, McGinley J . Determinants of health-related quality of life in Parkinson's disease: a systematic review. Parkinsonism Relat Disord. 2010; 17(1):1-9. DOI: 10.1016/j.parkreldis.2010.08.012. View

3.
Wu Y, Guo X, Wei Q, Song W, Chen K, Cao B . Determinants of the quality of life in Parkinson's disease: results of a cohort study from Southwest China. J Neurol Sci. 2014; 340(1-2):144-9. DOI: 10.1016/j.jns.2014.03.014. View

4.
HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

5.
Gibb W, Lees A . The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988; 51(6):745-52. PMC: 1033142. DOI: 10.1136/jnnp.51.6.745. View